SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Tseng Lab on the move?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: muddphudd who wrote (222)10/26/1998 3:48:00 PM
From: Urlman   of 251
 
REAL AUDIO PROGRAM WITH CELL PATHWAY Hosted by Lou Cattaruzza

http://www.audionet.com/business/events/wcn/cell_sys.ram

WCNradio – Cell Pathways’ President and CEO Bob Towarnicki elaborates on the company’s May 20 report on the success of its Phase II extension study of FGN-1 in the treatment of Familial
Adenomatous Polyposis, a genetic disorder resulting in colon cancer. Significantly, the drug provides a novel, highly selective means for inducing programmed cell death, or apotosis, in precancerous and cancerous lesions, which leaves healthy cells unharmed. The company is also conducting studies on the use of FGN-1 in the treatment of prostate, lung and breast cancer. Although the company postponed a scheduled IPO due
to market conditions for biotech companies, Towarnicki is pleased with the company’s successful $18 million private financing.

======
If you are a fan of Real Audio please visit my website killpopradio.com


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext